Detail of "146939-27-7"

CAS Number:
146939-27-7
Name:
2H-Indol-2-one,5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-
Superlist Name:
Ziprasidone
Molecular Structure:
Formula:
C₂₁H₂₁ClN₄OS
Molecular Weight:
412.94
Synonyms:
5-[2-[4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-2-indolinone;5-[2-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one;CP 88059;Geodon;Zaprasidone;
Density:
1.369 g/cm³
Melting Point:
213-215 °C
Boiling Point:
554.8 °C at 760 mmHg
Flash Point:
289.3 °C
Appearance:
tan solid

Famous Chemical Enterprises

Livzon
Total
Shell
Dupont
Exxonmobil
Akzonobel
Basf
Bayer
BP

Other Products

Supplier Location
Supplier Location
- China (Mainland)(17)
- India(3)
- United States(3)
Business Type
Business Type
- Lab/Research institutions(1)
- Manufacturers(0)
- Trading Company(17)
Certificates
Certificates
- ISO(1)
- Production License (0)

Please post your buying leads>>

Display：

Manufacturer
Enterprise Authentication
Suppiers of more reward points first
New supplier

Please post your buying leads,so that our qualified suppliers will soon contact you!
*Required Fields

Reference

Tolerability of ziprasidone: an expanding perspective: Tolerability of ziprasidone: an expanding perspective.Several substances are used for example 146939-27-7 and 50-99-7 which are their cas registry numbers. Daniel, David G. (Bioniche Development, Inc., McLean, VA 22106-6207, USA). Journal of Clinical Psychiatry, 64(Suppl. 19), 40-49 (English) 2003 Physicians Postgraduate Press, Inc. CODEN: JCLPDE. ISSN: 0160-6689. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) Section cross-reference(s): 63 A review. Although atypical antipsychotic agents have improved the management of patients with schizophrenia, their utility has been hindered by some limitations, including significant wt. gain, glucose metab. disturbances, and increases in total and low-d. lipoprotein cholesterol and triglyceride levels. In addn. to its low liability for movement disorders and its favorable tolerability record in short- and long-term clin. trials, ziprasidone is assocd. with a favorable metabolic safety profile (in terms of its effect on plasma lipid and glucose levels) and a negligible effect on wt. The limited effect of ziprasidone on the cor. QT interval (QTc) has also been well characterized, and experience to date has not demonstrated any increased risk of clin. events attributable to QTc prolongation. This review of pharmacokinetic and clin. trials of ziprasidone vs. placebo and active comparators focuses on the safety and tolerability of both the i.m. and oral formulations. .

The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice: The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. Stahl, Stephen M.; Shayegan, Darius K. (Department of Psychiatry, University of California San Diego, USA). Journal of Clinical Psychiatry, 64(Suppl.Chemical with cas number 146939-27-7 also plays role. 19), 6-12 (English) 2003 Physicians Postgraduate Press, Inc. CODEN: JCLPDE. ISSN: 0160-6689. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) A review. Schizophrenia is a highly complex disorder characterized by a diversity of symptoms, psychotic and nonpsychotic, that most likely arise from heterogeneous neuroanatomical and neurochem. malfunctions. As with all antipsychotic agents, ziprasidone targets the key hypothetical neurochem. disturbance in psychosis-excessive dopamine neurotransmission at dopamine D2 receptors in the mesolimbic pathway of the brain-presumably responsible for the pos. symptoms of schizophrenia. Like other atypical antipsychotic agents, ziprasidone is a serotonin-2A (5-HT2A)/dopamine D2 antagonist; however, its in vitro 5-HT2A/D2 receptor affinity ratio is higher than that of the other first-line atypical antipsychotic agents (namely, risperidone, olanzapine, quetiapine, and aripiprazole). Ziprasidone also exhibits potent interaction with 5-HT2C, 5-HT1D, and 5-HT1A receptors in human brain tissue, characteristics that predict heightened neg. symptom relief, enhanced modulation of mood, cognitive improvement, and reduced motor dysfunction. Ziprasidone has moderate affinity for serotonin and norepinephrine reuptake sites, predicting antidepressant/anxiolytic activity. On the other hand, ziprasidone's low affinity for a1-adrenoceptors, as well as histamine H1 and muscarinic M1 receptors, suggests that patients should experience relatively little orthostatic hypotension, sedation, cognitive disturbance, wt. gain, or dysregulation of prolactin levels. Efficacy and tolerability data from trials to date indicate that ziprasidone's clin. activity is consistent with its receptor profile. .

Detail of "146939-27-7"

2H-Indol-2-one,5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-

Famous Chemical Enterprises

Related products

Other Products

Supplier Location

Business Type

Certificates

CAS No.146939-27-7 Ziprasidone

CAS No.146939-27-7 Ziprasidone

CAS No.146939-27-7 Ziprasidone

CAS No.146939-27-7 Ziprasidone

CAS No.146939-27-7 Ziprasidone

CAS No.146939-27-7 Ziprasidone

CAS No.146939-27-7 Ziprasidone

CAS No.146939-27-7 Ziprasidone

CAS No.146939-27-7 Ziprasidone

CAS No.146939-27-7 Ziprasidone

CAS No.146939-27-7 Ziprasidone

CAS No.146939-27-7 Ziprasidone

CAS No.146939-27-7 Ziprasidone

CAS No.146939-27-7 Ziprasidone

CAS No.146939-27-7 Ziprasidone

CAS No.146939-27-7 Ziprasidone

CAS No.146939-27-7 Ziprasidone

CAS No.146939-27-7 Ziprasidone

CAS No.146939-27-7 Ziprasidone

CAS No.146939-27-7 Ziprasidone

CAS No.146939-27-7 Ziprasidone

CAS No.146939-27-7 Ziprasidone

CAS No.146939-27-7 Ziprasidone

Reference